Structure Therapeutics To Present Late-Breaking ADA Data on Oral Amylin Agonist ACCG-2671

Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in.

Structure Therapeutics Inc. (NASDAQ:GPCR) showcased preclinical findings for ACCG-2671 and GSBR-5595 in two late-breaking posters at the ADA 85th Scientific Sessions. ACCG-2671, an oral dual amylin and calcitonin receptor agonist, led to considerable, dose-dependent weight loss in obese rats and improved outcomes when coupled with semaglutide. Clinical studies are anticipated to begin before the end of 2025. A GLP-1 receptor agonist called GSBR-5595 has shown neuroprotective effects in animal models of Parkinson’s disease by enhancing motor function and raising the number of dopaminergic neurons.

CEO Raymond Stevens pointed out ACCG-2671’s potential as a distinct oral medication for obesity, citing expanding evidence of amylin receptor targeting. Poster #2184-LB described ACCG-2671’s high binding affinity for human CTR and AMY3R receptors, as well as its synergistic effect with semaglutide in encouraging superior weight reduction. The benefit of GSBR-5595 in Parkinson’s models was noted in Poster #1985-LB, showing that GLP-1 receptor agonists might have many uses. These findings support Structure Therapeutics Inc. (NASDAQ:GPCR)’s plan to provide injectable therapy substitutes with scalable oral small molecules. It is one of the Best Weight Loss Stocks.

While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.